Arcutis Biotherapeutics Q4 2023 GAAP EPS $(0.72) Beats $(0.76) Estimate, Sales $13.53M Beat $11.34M Estimate
Author: Benzinga Newsdesk | February 27, 2024 06:55am
Arcutis Biotherapeutics (NASDAQ:
ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.76) by 5.26 percent. The company reported quarterly sales of $13.53 million which beat the analyst consensus estimate of $11.34 million by 19.28 percent. This is a 356.81 percent increase over sales of $2.96 million the same period last year.
Posted In: ARQT